Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812202 | 0.84 | HSD11B1 (0.43) | ALDH1A1 | |
| SCHEMBL3813595 | 0.84 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1POLBLMNAMAPT | |
| SCHEMBL26135641 | 0.84 | AKR1C1 (0.44) | — | |
| SCHEMBL4849593 | 0.80 | PARP15 (0.41) | POLBPARP10LMNACYP19A1RAB9A | |
| SCHEMBL11289324 | 0.80 | AKR1C1 (0.48) | LMNA | |
| SCHEMBL15258665 | 0.79 | MAPT (0.44) | ALDH1A1L3MBTL1POLBLMNAMAPT | |
| SCHEMBL11275197 | 0.79 | AKR1C1 (0.47) | — | |
| SCHEMBL27878075 | 0.78 | POLB (0.36) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL2720271 | 0.78 | GSK3B (0.42) | — | |
| SCHEMBL2720401 | 0.76 | CA1 (0.37) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459036-B | Process for the preparation of 3- (3- (4- (1-aminocyclobutyl) phenyl) -5-phenyl-3H-imidazo [4,5-b ] pyridin-2-yl) pyridin-2-amine | 艾科尔公司 | 2021-07-16 | — | — | CN | claimed |
| CN-117486876-A | Compounds as inhibitors of Akt kinase | 正大天晴药业集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116194452-A | Compounds as inhibitors of Akt kinase | 正大天晴药业集团股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-106459036-B | Process for the preparation of 3- (3- (4- (1-aminocyclobutyl) phenyl) -5-phenyl-3H-imidazo [4,5-b ] pyridin-2-yl) pyridin-2-amine | 艾科尔公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-111494378-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-107074769-B | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-04-07 | — | — | CN | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| CN-107074769-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | ALDH1A1 1940/4885L3MBTL1 2612/4885POLB 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.